HK1083451A1 - N-aryl piperidine substituted biphenylcarboxamidesas inhibitors of apolipoprotein B secretion - Google Patents
N-aryl piperidine substituted biphenylcarboxamidesas inhibitors of apolipoprotein B secretionInfo
- Publication number
- HK1083451A1 HK1083451A1 HK06103425A HK06103425A HK1083451A1 HK 1083451 A1 HK1083451 A1 HK 1083451A1 HK 06103425 A HK06103425 A HK 06103425A HK 06103425 A HK06103425 A HK 06103425A HK 1083451 A1 HK1083451 A1 HK 1083451A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- biphenylcarboxamidesas
- apolipoprotein
- secretion
- inhibitors
- piperidine substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02078309 | 2002-08-12 | ||
| PCT/EP2003/008694 WO2004017969A1 (en) | 2002-08-12 | 2003-08-05 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1083451A1 true HK1083451A1 (en) | 2006-07-07 |
Family
ID=31896911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK06103425A HK1083451A1 (en) | 2002-08-12 | 2006-03-17 | N-aryl piperidine substituted biphenylcarboxamidesas inhibitors of apolipoprotein B secretion |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20060040989A1 (xx) |
| EP (1) | EP1536796B1 (xx) |
| JP (1) | JP4559856B2 (xx) |
| KR (1) | KR101052204B1 (xx) |
| CN (3) | CN101165053A (xx) |
| AR (1) | AR040968A1 (xx) |
| AT (1) | ATE385796T1 (xx) |
| AU (1) | AU2003250215B2 (xx) |
| BR (1) | BR0313377A (xx) |
| CA (1) | CA2494208C (xx) |
| CY (1) | CY1107945T1 (xx) |
| DE (1) | DE60319097T2 (xx) |
| DK (1) | DK1536796T3 (xx) |
| EA (1) | EA008061B1 (xx) |
| EG (1) | EG25699A (xx) |
| ES (1) | ES2301873T3 (xx) |
| HK (1) | HK1083451A1 (xx) |
| HR (1) | HRP20050103B1 (xx) |
| IL (1) | IL166795A (xx) |
| IS (1) | IS2726B (xx) |
| MX (1) | MXPA05001712A (xx) |
| MY (1) | MY136632A (xx) |
| NO (1) | NO329308B1 (xx) |
| NZ (1) | NZ538680A (xx) |
| PA (1) | PA8579901A1 (xx) |
| PL (1) | PL212405B1 (xx) |
| PT (1) | PT1536796E (xx) |
| SI (1) | SI1536796T1 (xx) |
| TW (1) | TWI342775B (xx) |
| UA (1) | UA79300C2 (xx) |
| WO (1) | WO2004017969A1 (xx) |
| ZA (1) | ZA200501225B (xx) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83510C2 (xx) * | 2003-12-09 | 2008-07-25 | Янссен Фармацевтика Н.В. | N-арилпіперидин заміщені біфенілкарбоксаміди як інгібітори аполіпопротеїну b$n-арилпиперидин замещенные бифенилкарбоксамиды как ингибиторы аполипопротеина b |
| FR2883000B1 (fr) | 2005-03-14 | 2007-06-01 | Merck Sante Soc Par Actions Si | Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| EP1948629A1 (en) | 2005-10-31 | 2008-07-30 | Janssen Pharmaceutica N.V. | Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor |
| US8163708B2 (en) * | 2006-04-03 | 2012-04-24 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotide |
| CA3024953A1 (en) | 2006-04-03 | 2007-10-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| US20080249130A1 (en) * | 2007-02-09 | 2008-10-09 | Sirtris Pharmaceuticals, Inc. | Gut microsomal triglyceride transport protein inhibitors |
| US8580756B2 (en) * | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
| CA2681406A1 (en) * | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of apo-b100 expression |
| CA2697970A1 (en) * | 2007-08-30 | 2009-03-05 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of fabp4/ap2 |
| ATE505454T1 (de) * | 2007-09-20 | 2011-04-15 | Amgen Inc | 1-(4-(4-benzylbenzamid)-benzyl)-azetidin-3- carboxylsäurederivate und entsprechende verbindungen als s1p-rezeptor-modulatoren zur behandlung von immunerkrankungen |
| EA019939B1 (ru) | 2007-10-04 | 2014-07-30 | Сантарис Фарма А/С | МОДИФИЦИРОВАННЫЙ ОЛИГОМЕР ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА микроРНК В КЛЕТКЕ |
| EP2268811A1 (en) * | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| EP2315832B1 (en) | 2008-08-01 | 2015-04-08 | Roche Innovation Center Copenhagen A/S | Micro-rna mediated modulation of colony stimulating factors |
| WO2010122538A1 (en) * | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
| US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
| SI3013959T1 (sl) | 2013-06-27 | 2020-04-30 | Roche Innovation Center Copenhagen A/S | Protismiselni oligomeri in konjugati, ki ciljajo PCSK9 |
| US9790237B2 (en) | 2014-06-16 | 2017-10-17 | Johnson Matthey Public Limited Company | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| MX7065E (es) * | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
| US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
| US4647576A (en) * | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
| US4847271A (en) * | 1986-01-27 | 1989-07-11 | Merck & Co., Inc. | Antihypercholesterolemic β-lactones |
| US5041432A (en) * | 1987-01-30 | 1991-08-20 | E. I. Du Pont De Nemours And Company | Steroid derivatives useful as hypocholesterolemics |
| US5064856A (en) * | 1989-07-31 | 1991-11-12 | Merck & Co., Inc. | Novel hmg-coa synthase inhibitors |
| US5120729A (en) * | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| EP0618803A4 (en) * | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS. |
| DE69332792T2 (de) | 1992-04-20 | 2004-01-15 | Takeda Chemical Industries Ltd | 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide |
| AU678503B2 (en) | 1993-09-24 | 1997-05-29 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds and their use as squalene synthetase inhibitors |
| WO1996010559A1 (en) | 1994-10-04 | 1996-04-11 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives and their use as acat-inhibitors |
| US5510379A (en) * | 1994-12-19 | 1996-04-23 | Warner-Lambert Company | Sulfonate ACAT inhibitors |
| GB9504066D0 (en) | 1995-03-01 | 1995-04-19 | Pharmacia Spa | Phosphate derivatives of ureas and thioureas |
| PL336481A1 (en) * | 1997-04-18 | 2000-06-19 | Pfizer | Method of obtaining (1,2,3,4- tetrahydroisoquinolin -6-yl) amide of 4'-trifluoromethylbiphenyl-2-carboxylic acid and intermediate compounds |
| GB9826412D0 (en) * | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
| GB0013378D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
| GB0013383D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| JO2654B1 (en) * | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
| JO2409B1 (en) * | 2000-11-21 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Second-phenyl carboxy amides are useful as lipid-lowering agents |
| JO2390B1 (en) * | 2001-04-06 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Diphenylcarboxamides act as lipid-lowering agents |
| ES2217245T3 (es) * | 2001-06-27 | 2004-11-01 | Rs Tech Corp. | Nuevo catalizador saleno quiral y metodos de obtencion de compuestos quirales a partir de epoxidos racemicos utilizando el nuevo catalizador. |
| GB0129015D0 (en) * | 2001-12-04 | 2002-01-23 | Glaxo Group Ltd | Compounds |
-
2003
- 2003-05-08 UA UAA200501990A patent/UA79300C2/uk unknown
- 2003-08-02 EG EG2003080749A patent/EG25699A/xx active
- 2003-08-05 DE DE60319097T patent/DE60319097T2/de not_active Expired - Lifetime
- 2003-08-05 AU AU2003250215A patent/AU2003250215B2/en not_active Ceased
- 2003-08-05 PT PT03792260T patent/PT1536796E/pt unknown
- 2003-08-05 MX MXPA05001712A patent/MXPA05001712A/es active IP Right Grant
- 2003-08-05 CN CNA2007101866745A patent/CN101165053A/zh active Pending
- 2003-08-05 AT AT03792260T patent/ATE385796T1/de active
- 2003-08-05 DK DK03792260T patent/DK1536796T3/da active
- 2003-08-05 CA CA2494208A patent/CA2494208C/en not_active Expired - Fee Related
- 2003-08-05 WO PCT/EP2003/008694 patent/WO2004017969A1/en active IP Right Grant
- 2003-08-05 EA EA200500348A patent/EA008061B1/ru not_active IP Right Cessation
- 2003-08-05 NZ NZ538680A patent/NZ538680A/en not_active IP Right Cessation
- 2003-08-05 JP JP2004530089A patent/JP4559856B2/ja not_active Expired - Fee Related
- 2003-08-05 EP EP03792260A patent/EP1536796B1/en not_active Expired - Lifetime
- 2003-08-05 ES ES03792260T patent/ES2301873T3/es not_active Expired - Lifetime
- 2003-08-05 US US10/524,051 patent/US20060040989A1/en not_active Abandoned
- 2003-08-05 SI SI200331203T patent/SI1536796T1/sl unknown
- 2003-08-05 CN CN2007101866730A patent/CN101165052B/zh not_active Expired - Fee Related
- 2003-08-05 CN CNB03818592XA patent/CN100366252C/zh not_active Expired - Fee Related
- 2003-08-05 BR BR0313377-0A patent/BR0313377A/pt not_active Application Discontinuation
- 2003-08-05 KR KR1020057000829A patent/KR101052204B1/ko not_active IP Right Cessation
- 2003-08-05 PL PL373379A patent/PL212405B1/pl unknown
- 2003-08-07 PA PA20038579901A patent/PA8579901A1/es unknown
- 2003-08-08 MY MYPI20033022A patent/MY136632A/en unknown
- 2003-08-11 TW TW092121938A patent/TWI342775B/zh not_active IP Right Cessation
- 2003-08-11 AR ARP030102901A patent/AR040968A1/es not_active Application Discontinuation
-
2004
- 2004-12-29 IS IS7622A patent/IS2726B/is unknown
-
2005
- 2005-01-31 NO NO20050563A patent/NO329308B1/no not_active IP Right Cessation
- 2005-02-01 HR HRP20050103AA patent/HRP20050103B1/hr not_active IP Right Cessation
- 2005-02-10 ZA ZA200501225A patent/ZA200501225B/en unknown
- 2005-02-10 IL IL166795A patent/IL166795A/en unknown
-
2006
- 2006-03-17 HK HK06103425A patent/HK1083451A1/xx not_active IP Right Cessation
-
2008
- 2008-05-13 CY CY20081100504T patent/CY1107945T1/el unknown
-
2009
- 2009-01-09 US US12/351,385 patent/US8258304B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1083451A1 (en) | N-aryl piperidine substituted biphenylcarboxamidesas inhibitors of apolipoprotein B secretion | |
| SI1534290T1 (sl) | Novi inhibitorji kinaz | |
| EG25482A (en) | Inhibitors | |
| HK1080745A1 (en) | Angiogenesis inhibitors | |
| AU2002344567A1 (en) | Heterocyclic amide compounds as apolipoprotein b inhibitors | |
| AU2003298514A8 (en) | Methods and compositions using cholinesterase inhibitors | |
| HK1072362A1 (en) | Methods of inducing terminal differentiation | |
| IL165887A0 (en) | Novel tetrahydropyridine derivatives as renin inhibitors | |
| AU2003217105A8 (en) | Novel of cytokine inhibitors | |
| IL165475A0 (en) | Nitrooxyderivatives of eyclooxygenase-2 inhibitors | |
| AU2003232848A8 (en) | Phenylaminopyrimidines and their use as rho-kinase inhibitors | |
| EP1532133A4 (en) | NF-: B INHIBITORS | |
| EP1577280A4 (en) | DEUTERATION PROCESS | |
| EP1638565A4 (en) | SUBSTITUTED PIPERIDINE COMPOUNDS AND METHOD OF USE THEREOF | |
| AU2003299901A8 (en) | Thrombin inhibitors | |
| AU2003295638A8 (en) | Novel inhibitors of beta-lactamase | |
| EP1488046A4 (en) | CONSTRUCTION METHODS | |
| GB0223276D0 (en) | Cladding of rails | |
| AU2003304374A8 (en) | Peptide inhibitors of beta-lactamases | |
| AU2003215298A1 (en) | Alpha1beta1 antagonists for treatment of atherosclerosis | |
| IL161521A0 (en) | N-formyl derivatives of paroxetine | |
| AU2003299137A8 (en) | Inhibition of metallo-beta-lactamase | |
| PL376796A1 (pl) | Sposób wytwarzania inhibitorów fosfodiesterazy-4 | |
| GB0204088D0 (en) | Novel substituted heterocyclic inhibitors of catechol-o-methyl transperase | |
| GB0225854D0 (en) | Inhibitors of complement activation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180807 |